Press Releases

Press Releases

Samsung Biologics launches S-CHOice cell line technology

 

S-CHOice Launch Ceremony August 5,2020

 

Incheon, S. Korea, 5 August 2020 – Samsung Biologics (KRX: 207940.KS) today held an online ceremony to announce the launch of its proprietary cell line technology, S-CHOice.

 

S-CHOice builds on glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line technology and shows improved titers up to two-fold from industry average, reaching above 7 g/L for standard monoclonal antibodies. The cell line also shows enhanced cell viability with over 90% at day-21 in a fed-batch study, demonstrating effectiveness in producing high quality cell lines.

 

Moreover, S-CHOice has a speedy cell division of 18-20 hours and together with Berkeley Lights Beacon® technology, Samsung Biologics can offer reduced development timeline by a month from the industry average of four to five months.

 

The company will also provide attractive payment terms for clients choosing to use this cell line technology for their future development.  

 

Leveraging these combination of advantages, Samsung Biologics recently signed a development contract with a client under which S-CHOice will be used to advance its cell line development.

 

“We are extremely proud to announce the official launch of our own proprietary cell line, S-CHOice,” said Dr. Tae Han Kim, CEO of Samsung Biologics. “With this advanced, high performance technology, we can now offer our CDO clients with even more promising options in bringing their molecule faster and better to the market and ensure world-class client satisfaction during this continuously evolving global climate.”

 

 

S-CHOice Launch Ceremony August 5,2020

 

Incheon, S. Korea, 5 August 2020 – Samsung Biologics (KRX: 207940.KS) today held an online ceremony to announce the launch of its proprietary cell line technology, S-CHOice.

 

S-CHOice builds on glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line technology and shows improved titers up to two-fold from industry average, reaching above 7 g/L for standard monoclonal antibodies. The cell line also shows enhanced cell viability with over 90% at day-21 in a fed-batch study, demonstrating effectiveness in producing high quality cell lines.

 

Moreover, S-CHOice has a speedy cell division of 18-20 hours and together with Berkeley Lights Beacon® technology, Samsung Biologics can offer reduced development timeline by a month from the industry average of four to five months.

 

The company will also provide attractive payment terms for clients choosing to use this cell line technology for their future development.  

 

Leveraging these combination of advantages, Samsung Biologics recently signed a development contract with a client under which S-CHOice will be used to advance its cell line development.

 

“We are extremely proud to announce the official launch of our own proprietary cell line, S-CHOice,” said Dr. Tae Han Kim, CEO of Samsung Biologics. “With this advanced, high performance technology, we can now offer our CDO clients with even more promising options in bringing their molecule faster and better to the market and ensure world-class client satisfaction during this continuously evolving global climate.”

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION